Recon: Amgen signs $2B pact with Synaffix to develop antibody conjugates; Swedish EU presidency promises action on pharma law revision
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy